BRCAAWAY: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) with DNA repair defects.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Maha H. A. Hussain, Masha Kocherginsky, Neeraj Agarwal, Jingsong Zhang, Nabil Adra, Channing Judith Paller, Joel Picus, Zachery R Reichert, Russell Zelig Szmulewitz, Scott T. Tagawa, Young E. Whang, Robert Dreicer, Timothy Kuzel, Latifa Bazzi, Travis A. Gerke, Stephanie Daignault-Newton, Arul Chinnaiyan, Emmanuel S. Antonarakis
Institutions: Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, University of Utah, Huntsman Cancer Institute, Moffitt Cancer Center, Indiana University Health, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Johns Hopkins University, Washington University in St. Louis, University of Michigan, University of Chicago, Weill Cornell Medicine, University of North Carolina at Chapel Hill, University of Virginia Cancer Center, Rush University Medical Center, Masonic Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4286296414